Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: Risk factors and outcome

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages O694-O701

  Mikulska, M ^a,b   Nicolini, L ^a   Signori, A ^b   Rivoli, G ^a   Del Bono, V ^a   Raiola, A M ^a   Di Grazia, C ^a   Dominietto, A ^a   Varaldo, R ^a   Ghiso, A ^a   Bacigalupo, A ^a   Viscoli, C ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Bone marrow transplant; Chronic graft vs. host disease; Cyclosporin; Occult HBV; Resolved HBV hepatitis; Reverse seroconversion; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HEPATITIS B CORE ANTIBODY; LAMIVUDINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; CYCLOSPORIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REACTIVATION; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B VIRUS; IMMUNOLOGY; MALE; MIDDLE AGED; PHYSIOLOGY; SURVIVAL; VIRUS ACTIVATION; YOUNG ADULT;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84913612874     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12611     Document Type: Article

References (33)

1. Raimondo G, Allain JP, Brunetto MR et al. Statements from the taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657.
2. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165.
3. Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-hbs and anti-hbc. Transplantation 1998; 66: 616-619.
4. Seth P, Alrajhi AA, Kagevi I et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30: 189-194.
5. Zekri AR, Mohamed WS, Samra MA, Sherif GM, El-Shehaby AM, El-Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004; 13: 305-311.
6. Francisci D, Aversa F, Coricelli V et al. Prevalence, incidence and clinical outcome of hepatitis B virus and hepatitis C virus hepatitis in patients undergoing allogeneic hematopoietic stem cell transplantation between 2001 and 2004. Haematologica 2006; 91: 980-982.
7. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007; 14: 478-483.
8. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619.
9. Giaccone L, Festuccia M, Marengo A et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 809-817.
10. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049-1059.
11. Moses SE, Lim ZY, Sudhanva M et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 2006; 78: 1560-1563.
12. Vigano M, Vener C, Lampertico P et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic sct. Bone Marrow Transplant 2011; 46: 125-131.
13. Tomblyn M, Chen M, Kukreja M et al. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transpl Infect Dis 2012; 14: 468-478.
14. Frassoni F, Gualandi F, Podesta M et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase i/ii study. Lancet Oncol 2008; 9: 831-839.
15. Mikulska M, Raiola AM, Bruno B et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic sct from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44: 361-370.
16. Mikulska M, Raiola AM, Bruzzi P et al. Cmv infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative cmv serostatus. Biol Blood Marrow Transplant 2011; 18: 92-99.
17. Dominietto A, Tedone E, Soracco M et al. In vivo b-cell depletion with rituximab for alternative donor hemopoietic sct. Bone Marrow Transplant 2012; 47: 101-106.
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
19. Cortese G, Andersen PK. Competing risks and time-dependent covariates. Biom J 2010; 52: 138-158.
20. van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat 2006; 34: 70-85.
21. Coviello V, Boggess M. Cumulative incidence estimation in presence of competing risks. STATA J 2004; 4: 103-112.
22. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
23. Ramos CA, Saliba RM, de Padua Silva L et al. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 686-694.
24. Onozawa M, Hashino S, Darmanin S et al. Hb vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008; 14: 1226-1230.
25. Lau GK, Suri D, Liang R et al. Resolution of chronic hepatitis B and anti-hbs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-624.
26. Park S, Kim K, Kim DH et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol Blood Marrow Transplant 2012; 17: 1630-1637.
27. Tsutsumi Y, Ogasawara R, Kamihara Y et al. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010; 2010: 182067.
28. Marzano A, Angelucci E, Andreone P et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
29. Zaia J, Baden L, Boeckh MJ et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 471-482.
30. Raimondo G, Navarra G, Mondello S et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008; 48: 743-746.
31. Al-Mekhaizeem KA, Miriello M, Sherker AH. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 2001; 165: 1063-1064.
32. Evens AM, Jovanovic BD, Su YC et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-1180.
33. Hsu C, Tsou HH, Lin SJ et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2013. doi: 10.1002/hep.26718.